DUBLIN, Nov. 01, 2022 (GLOBE NEWSWIRE) — The “Crohn’s Disease Therapeutics Market Forecast – Epidemiology and Pipeline Analysis” Report has been added ResearchAndMarkets.com Offer.
Crohn’s disease is an inflammatory bowel disease (IBD) that causes inflammation of the digestive tract, resulting in abdominal pain, severe diarrhea, fatigue, weight loss and malnutrition. The inflammatory bowel disease treatment market can be segmented into two types namely Crohn’s disease and ulcerative colitis. Among these, Crohn’s disease dominates the world market.
According to estimates, the prevalence of Crohn’s disease in 2020 was high in the United States, followed by the United Kingdom and China. The increasing prevalence of Crohn’s disease is driving the growth of the Crohn’s disease drug market. It is estimated that one million people in the United States were affected by Crohn’s disease in 2019.
Crohn’s Disease Therapeutics: Pipeline Scenario
The Crohn’s disease portfolio comprises a total of over 100 assets at various stages of development. Most of the industry-sponsored drugs in active clinical development for Crohn’s disease are in phase II. Anti-interleukin and integrin antibodies dominate the drug pipeline for Crohn’s disease.
Therapeutics for Crohn’s disease: scenario for clinical trials
The portfolio of clinical studies includes more than 150 studies in various stages of development. Most of the industry-sponsored drugs in active clinical development for Crohn’s disease are in Phase II. The distribution of clinical trials across Phases I-IV shows that the vast majority of Crohn’s disease trials are in the early and mid-phase in development, with 75-80% of the studies in phase I-II and only 16% in phase III-IV. The US has a significant lead in the number of clinical trials for Crohn’s disease worldwide.
Market leader:
Introduction of biologics: Biologic therapies such as anti-tumor necrosis factor (TNF), anti-interleukin and integrin antibodies are widely used for various inflammatory diseases such as…
